GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (NAS:AXDX) » Definitions » ROE %

Accelerate Diagnostics (Accelerate Diagnostics) ROE % : 0.00% (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Accelerate Diagnostics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Accelerate Diagnostics's annualized net income for the quarter that ended in Mar. 2024 was $-56.92 Mil. Accelerate Diagnostics's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $-22.83 Mil. Therefore, Accelerate Diagnostics's annualized ROE % for the quarter that ended in Mar. 2024 was N/A%.

The historical rank and industry rank for Accelerate Diagnostics's ROE % or its related term are showing as below:

AXDX's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -0.16
* Ranked among companies with meaningful ROE % only.

Accelerate Diagnostics ROE % Historical Data

The historical data trend for Accelerate Diagnostics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics ROE % Chart

Accelerate Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -337.25 - - - -

Accelerate Diagnostics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - Negative Equity - -

Competitive Comparison of Accelerate Diagnostics's ROE %

For the Medical Devices subindustry, Accelerate Diagnostics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerate Diagnostics's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's ROE % distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's ROE % falls into.



Accelerate Diagnostics ROE % Calculation

Accelerate Diagnostics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-61.618/( (-22.264+-19.888)/ 2 )
=-61.618/-21.076
=N/A %

Accelerate Diagnostics's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-56.92/( (-19.888+-25.78)/ 2 )
=-56.92/-22.834
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Accelerate Diagnostics  (NAS:AXDX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-56.92/-22.834
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-56.92 / 11.684)*(11.684 / 31.044)*(31.044 / -22.834)
=Net Margin %*Asset Turnover*Equity Multiplier
=-487.16 %*0.3764*N/A
=ROA %*Equity Multiplier
=-183.37 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-56.92/-22.834
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-56.92 / -56.92) * (-56.92 / -40.624) * (-40.624 / 11.684) * (11.684 / 31.044) * (31.044 / -22.834)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.4011 * -347.69 % * 0.3764 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Accelerate Diagnostics ROE % Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerate Diagnostics (Accelerate Diagnostics) Business Description

Traded in Other Exchanges
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Executives
David Patience officer: Chief Financial Officer C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714
Jack Phillips director, officer: PRESIDENT AND CEO 11731 YALE DR, CARMEL IN 46032
Larry Michael Mertz officer: Chief Technology Officer 3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714
Marran H. Ogilvie director 599 LEXINGTON AVENUE, NEW YORK NY 10022
Jennifer Regan director C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Mark S. Black director 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Steven Reichling officer: CFO 7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221
Ron Price officer: SVP & HEAD OF COM OPS AMERICAS 3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Wayne Burris director 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Mark C Miller director C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045
Ten Brink Frank Jm director C/O STERICYCLE INC, 28161 N KEITH DR, LAKE FOREST IL 60045
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Louise Francesconi director 870 WINTER STREET, WALTHAM MA 02451

Accelerate Diagnostics (Accelerate Diagnostics) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold Accelerate Diagnostics Inc Shares

By GuruFocus Research GuruFocus Editor 05-18-2023